Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-08-08 |
2023-06 |
0 |
N/A |
N/A |
N/A |
2023-07-06 |
2023-03 |
0 |
N/A |
N/A |
N/A |
2023-04-03 |
2022-12 |
-2.2 |
N/A |
N/A |
N/A |
2022-11-14 |
2022-09 |
-2.06 |
N/A |
N/A |
N/A |
2022-08-11 |
2022-06 |
-1.77 |
N/A |
N/A |
N/A |
2022-05-12 |
2022-03 |
-1.75 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-08-16 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Buy |
2020-11-17 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2020-11-17 |
H.C. Wainwright |
Downgrade |
Buy |
Neutral |
2020-11-25 |
H.C. Wainwright |
Upgrade |
|
Buy |
2020-11-25 |
H.C. Wainwright |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2016-01-07 |
ADAMS ROBERT W |
Director |
0.00 |
Stock Award(Grant) |
2016-01-07 |
BYRNE THOMAS S JD |
Director |
1.39M |
Stock Award(Grant) |
2023-01-30 |
COBUZZI ROBERT JOSEPH JR |
Chief Executive Officer |
1.62K |
Conversion of Exercise of derivative security |
2022-04-17 |
ELDER WILLIAM ROBERT |
General Counsel |
400.00 |
Conversion of Exercise of derivative security |
2016-01-07 |
GAINER JOHN L. PHD |
Officer and Director |
0.00 |
Stock Award(Grant) |
2016-12-27 |
GILES MARK T |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-03-30 |
Vanguard Group, Inc. (The) |
72.76K |
224.84K |
3.57% |
2023-03-30 |
Renaissance Technologies, LLC |
39.11K |
120.85K |
1.92% |
2023-03-30 |
Blackrock Inc. |
32.85K |
101.51K |
1.61% |
2023-03-30 |
Citadel Advisors Llc |
18.66K |
57.65K |
0.91% |
2023-03-30 |
Geode Capital Management, LLC |
17.12K |
52.91K |
0.84% |
2023-03-30 |
Bridgeway Capital Management, Inc. |
16.57K |
51.19K |
0.81% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Vanguard Total Stock Market Index Fund |
41.00K |
126.70K |
2.01% |
2022-12-30 |
Vanguard Extended Market Index Fund |
28.98K |
89.54K |
1.42% |
2022-12-30 |
Bridgeway Funds Inc-Ultra Small Company Fund |
16.57K |
51.19K |
0.81% |
2023-02-27 |
Fidelity Extended Market Index Fund |
10.03K |
30.98K |
0.49% |
2023-01-30 |
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF |
6.10K |
18.85K |
0.30% |
2023-02-27 |
Fidelity NASDAQ Composite Index Fund |
2.37K |
7.31K |
0.12% |
Split |
Date |
1 : 50 |
2022-04-19 |
1 : 15 |
2018-12-14 |
1 : 10 |
2016-08-19 |
1 : 100 |
2014-03-10 |